Patents by Inventor Jonathan A. Bard

Jonathan A. Bard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
    Patent number: 5976814
    Abstract: This invention provides methods for determining whether a chemical compound specifically binds to and activates or inhibits activation of a human or rat Y4 receptor.
    Type: Grant
    Filed: January 13, 1997
    Date of Patent: November 2, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
  • Processes for identifying compounds that bind to the human Y4 receptor
    Patent number: 5958709
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.
    Type: Grant
    Filed: November 8, 1995
    Date of Patent: September 28, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
  • DNA endoding human alpha 1 adrenergic receptors
    Patent number: 5861309
    Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: January 19, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Richard L. Weinshank, Carlos Forray
  • DNA encoding human alpha 1 adrenergic receptors and uses thereof
    Patent number: 5714381
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 3, 1998
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Carlos Forray, Richard L. Weinshank
  • DNA encoding human .alpha..sub.1 adrenegric receptors and uses thereof
    Patent number: 5556753
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor and an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, an isolated protein which is a human .alpha..sub.1a adrenergic receptor, an isolated protein which is .alpha..sub.1b adrenergic receptor and a isolated protein which is a human .alpha..sub.1c adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor, and vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, mammalian cells comprising such vectors, antibodies directed to the human .alpha..sub.1a adrenergic receptor, antibodies directed to the human .alpha..sub.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: September 17, 1996
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Carlos Forray, Richard L. Weinshank
  • DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
    Patent number: 5516653
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: May 14, 1996
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Mary W. Walker, Theresa Branchek, Richard L. Weinshank